Patients with T1aN0 NSCLC have typically been treated with lobectomy versus sublobar resection, according to Nasser Altorki, MD, based on previous research that revealed worse outcomes with sublobar resection, such as an...
For patients with advanced NSCLC, indefinite duration of immunotherapy treatment does not seem to offer benefits over fixed-duration therapy for 2 years, according to a study published in JAMA Oncology to coincide with the 2023...